Mutations in the tyrosine kinase domain of Anaplastic lymphoma kinase (ALK) have also been identified in N.B. FDA approved a series of ALK tyrosine kinase inhibitors (TKIs) for use in ALK-driven cancers [23]. Here, ALK is linked to cancer.